Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$160.0 million","upfrontCash":"Undisclosed","newsHeadline":"Acumen Pharmaceuticals Announces Pricing of Upsized Initial Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Hoag","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoag Enrolling Patients for Clinical Trial of Promising New Investigational Treatment for Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acumen Publishes Phase 1 Trial Design and Clinical Development Plan for ACU193, an Anti-Amyloid Beta Oligomer Antibody for Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of ACU193, First Monoclonal Antibody Developed to Selectively Target Toxic A\u03b2 Oligomers in Patients with Early Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Acumen Pharmaceuticals Announces Proposed Public Offering of Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"Undisclosed","newsHeadline":"Acumen Announces Pricing of Upsized $130 Million Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE\u00ae Technology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"K2 HealthVentures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Lonza Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II\/ Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by Acumen

    Menu

    Acumen

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Acumen Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's Disease

              Details:

              Lonza will manufacture the ACU193 (sabirnetug) drug substance, the first monoclonal antibody candidate to enter the clinic developed to selectively target toxic soluble amyloid beta oligomers, which evidence indicates are a primary underlying cause of Alzheimer’s disease.

              Lead Product(s): Sabirnetug

              Therapeutic Area: Neurology Product Name: ACU193

              Highest Development Status: Phase II/ Phase III Product Type: Large molecule

              Recipient: Lonza Group

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 04, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Acumen Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures

              Details:

              The proceends will be used to support development of a subcutaneous formulation of ACU193, a humanized monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers.

              Lead Product(s): ACU193

              Therapeutic Area: Neurology Product Name: ACU193

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: K2 HealthVentures

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Financing November 13, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Acumen Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE® Technology

              Details:

              The collaboration will provide Acumen access to Halozyme's ENHANZE® drug delivery technology, based on a recombinant human hyaluronidase PH20 enzyme (rHuPH20), for the development of a subcutaneous formulation of ACU193, the first clinical-stage AβO-targeting antibody.

              Lead Product(s): ACU193

              Therapeutic Area: Neurology Product Name: ACU193

              Highest Development Status: Phase I Product Type: Large molecule

              Recipient: Halozyme Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration November 06, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Acumen Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Acumen Announces Pricing of Upsized $130 Million Public Offering

              Details:

              Acumen intends to use its net proceeds to fund the Phase 2 portion of a future, potential Phase 2/3 adaptable trial of ACU193, an anti-AβO mAb developed to selectively target and inhibit toxic soluble AβOs, to fund chemistry, manufacturing and other R&D activities.

              Lead Product(s): ACU193

              Therapeutic Area: Neurology Product Name: ACU193

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: BofA Securities

              Deal Size: $130.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering July 18, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Acumen Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Acumen Pharmaceuticals Announces Proposed Public Offering of Common Stock

              Details:

              Acumen intends to use its net proceeds to fund the Phase 2 portion of a future, potential Phase 2/3 adaptable trial of ACU193, an anti-AβO mAb developed to selectively target and inhibit toxic soluble AβOs, to fund chemistry, manufacturing and other R&D activities.

              Lead Product(s): ACU193

              Therapeutic Area: Neurology Product Name: ACU193

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: BofA Securities

              Deal Size: $100.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering July 17, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Acumen Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of ACU193, First Monoclonal Antibody Developed to Selectively Target Toxic Aβ Oligomers in Patients with Early...

              Details:

              ACU193 is a humanized monoclonal antibody (mAb), it selectively targets toxic soluble AβOs whic is the primary underlying cause of the neurodegenerative process in alzheimer’s disease.

              Lead Product(s): ACU193

              Therapeutic Area: Neurology Product Name: ACU193

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 13, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Acumen Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Acumen Publishes Phase 1 Trial Design and Clinical Development Plan for ACU193, an Anti-Amyloid Beta Oligomer Antibody for Alzheimer’s Disease

              Details:

              ACU193 is a humanized monoclonal antibody discovered and developed based on its selectivity for soluble AβOs, which scientific evidence indicates are the most toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques.

              Lead Product(s): ACU193

              Therapeutic Area: Neurology Product Name: ACU193

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 01, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Acumen Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Hoag Enrolling Patients for Clinical Trial of Promising New Investigational Treatment for Alzheimer's Disease

              Details:

              ACU193 targets amyloid-beta oligomers and is a different approach to treating Alzheimer's disease than currently approved medications. ACU193 is designed to locate and bind to amyloid-beta oligomers – proteins that build up in the brain.

              Lead Product(s): ACU193

              Therapeutic Area: Neurology Product Name: ACU193

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Hoag

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 20, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Acumen Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Acumen Pharmaceuticals Announces Pricing of Upsized Initial Public Offering

              Details:

              Acumen is currently focused on advancing a targeted immunotherapy drug candidate, ACU193, to establish proof of mechanism in early AD patients. Acumen initiated its Phase 1 clinical trial of ACU193 in the second quarter of 2021.

              Lead Product(s): ACU193

              Therapeutic Area: Neurology Product Name: ACU193

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: BofA Securities

              Deal Size: $160.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering June 30, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY